The continuing clinical use of (S)NRIs to treat anxiety and depression as well as the recent developments of NET inhibitors as potential treatment for incontinence11, excessive sleepiness12 and neuropathic pain13,14 still warrant the discovery of novel NET inhibitors. The gene discussed is SLC6A2; the disease is depressive symptom measurement.